Abstract
Background Corpus callosum anomalies are commonly noted in autism spectrum disorder (ASD). Given the complexity of its microstructural architecture, with crossing fibers projecting throughout, we applied fixel-based analysis to probe white matter micro- and macrostructure within this region. As ASD is a neurodevelopmental condition with noted abnormalities in brain growth, age was also investigated.
Methods Data for participants with (N=54) and without (N=50) ASD, aged 5-34 years, were obtained from the Autism Brain Imaging Data Exchange-II (ABIDE-II). Within each site, indices of fiber density (FD), fiber cross-section (FC), and combined fiber density and cross-section (FDC) were compared between those groups.
Results Young adolescents with ASD (age = 11.19 ± 7.54) showed reduced macroscopic FC and FDC compared to age-matched neurotypical controls (age = 10.04 ± 4.40). Reduced FD and FDC was noted in a marginally older ASD (age 13.87 ± 3.15) cohort compared to matched controls (age = 13.85 ± 2.90). Among the oldest cohorts, a non-significant trend indicated reduced FD in older adolescents/young adults with ASD (age = 17.07 ± 3.56) compared to controls (age = 16.55 ± 2.95). There was a positive correlation between age and callosal mean FC and FDC in the youngest cohort. When stratified by diagnosis, this finding remained only for the ASD sample.
Conclusion White matter aberration appears greatest among younger ASD cohorts. In older adolescents and young adults, less of the corpus callosum seems affected. This supports the suggestion that some early neuropathophysiological indicators in ASD may dissipate with age.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by an Alfred Deakin Post-Doctoral Research Fellowship (Deakin University) held by MK. MS is supported by the Deakin University Postgraduate Research Scholarship (DUPR) PGE was supported by a Future Fellowship from the Australian Research Council (FT160100077)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only data that were openly available to the public before the initiation of the study were used. Data were obtained from the ABIDE-II (http://fcon_1000.projects.nitrc.org/indi/abide/abide_II.html) database.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All analysis scripts used in the present study are publicly available via: https://github.com/MervSingh/ABIDE-II_FBA.git. The ABIDE-II datasets are open source and can be downloaded from the following weblink: https://fcon_1000.projects.nitrc.org/indi/abide/.
